LYB001

Last updated

LYB001
Vaccine description
Target SARS-CoV-2
Vaccine type Virus-like particles
Clinical data
Routes of
administration
Intramuscular

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd. [1] [2] [3] [4]

It was found to be safe and well tolerated. [5]

References

  1. "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  2. "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov . 18 November 2021. NCT05125926. Retrieved 18 November 2021.
  3. "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
  4. "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov . 30 November 2021. NCT05137444. Retrieved 30 November 2021.
  5. Tang R, Zeng Y, Zhou Y, Liang Q, Kang W, Yang Z, et al. (2 May 2024). "Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study". Expert Review of Vaccines. 23 (1): 498–509. doi: 10.1080/14760584.2024.2337051 . PMID   38695310.